# US 2012/0252074 A1 · Pentose fermentation by a recombinant microorganism

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252074 A1
- Document ID: US20120252074A1
- Status: Published application
- Kind: A1
- Application number: 13/429,710
- Filed: 2012-03-26
- Published: 2012-10-04
- Earliest claimed: 2011-03-30
- Assignees: Codexis, Inc.
- Inventors: XIYUN ZHANG; RYAN C. FONG; EZHILKANI SUBBIAN
- Web page: https://patentgrep.com/patent/US20120252074A1

## CPC

- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12Y 101/01307: D-Xylose reductase (1.1.1.307)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides methods and compositions suitable for use in the conversion of xylose to xylitol and xylulose, including nucleic acid constructs, recombinant fungal host cells, and related materials.

## Claims

### Claim 1

An isolated xylose reductase variant, wherein said variant is has xylose reductase activity and comprises a substitution at one or more positions selected from 2, 3, 7, 11, 14, 17, 19, 20, 23, 24, 33, 36, 46, 47, 49, 56, 62, 63, 68, 86, 89, 97, 102, 107, 108, 114, 116, 123, 132, 134, 143, 152, 155, 157, 162, 168, 184, 206, 219, 224, 225, 226, 227, 228, 246, 231, 232, 233, 236, 240, 242, 245, 246, 249, 252, 255, 261, 264, 266, 267, 270, 271, 272, 275, 276, 279, 281, 282, 283, 285, 297, 299, 301, 302, 303, and/or 318, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:2.

### Claim 2 (depends on 1)

An isolated xylose reductase variant of claim 1, wherein said variant has xylose reductase activity and comprises a substitution at one or more positions selected from P2T, S3H, S3R, S3W, S3X, N7L, D11K, A14V, F17W, C19L, W20X, D23E, V24G, R33L, R33V, K36Q, E46C, E46K, D47G, D47N, A49G, K52R, A56E, A56Y, I62V, D63X, K68G, K68M, K68R, D86N, E89N, E89V, S97R, S97T, D102T, F107Y, L108Y, T114S, K116Q, K123C, K132A, K132N, D134E, D134H, D134V, I143L, K152A, K152E, K152H, K152Q, K155A, K155D, K155I, K155R, K155Y, G157R, I162L, P168S, S184A, R206S, R206V, Q219H, Q219L, Q219T, L224A, L224S, L224V, N225D, N225E, N225K, N225S, N225Y, Q226D, Q226E, Q226S, Q226V, G227D, R228T, N231G, N231H, N231L, N231S, T232A, T232C, T232S, T232V, S233C, S233F, S233G, S233I, S233K, S233V, S233X, F236L, T240V, K242L, A245S, A246L, A246S, G249D, P252C, V255I, S261A, S261C, S261N, S261T, G264D; A266V, A266C, I267V, I267X, K270R, S271G, N272P, P275A, R276M, R276F, R276W, W276M, E279Q, K281L, K281V, D282C, D282G, D282R, V283H, S285E, S285T, A297H, A297S, L299X, I301C, I301Y, N302D, N302G, N302S, L303I, L303V, and/or V318C, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:2.

### Claim 3 (depends on 1)

An isolated xylose reductase variant of claim 1, wherein said variant has xylose reductase activity and comprises at least one of the following substitutions and/or substitution sets P2T/S3H/A49G/P168S/S233K/R276W; P2T/S3X/A49G/S233X/I267X/R276W/L299X; P2T/C19L/E46C/A49G/F107Y/K132N/S233K/I267V/R276W; P2T/C19L/E46C/A49G/K132N/S233K/I267V/R276W; P2T/W20X/A49G/D63X/R276W; P2T/V24G/A49G; P2T/V24G/A49G/R276W; P2T/V24G/R276W/V318C; P2T/V24G/V318C; P2T/K36Q/A49G/G227D/R276W; P2T/E46C/A49G/F107Y/K132N/S233K/I267V/R276W; P2T/E46C/A49G/K132N/V164I/S233K/I267V/R276W; P2T/A49G; P2T/A49G/K52R/K152E/S233K/I267V/R276W; P2T/A49G/K52R/R206S/I267V/R276W; P2T/A49G/K52R/R276W; P2T/A49G/K68G/S261N/R276W/V318C; P2T/A49G/K68G/S261N/V318C; P2T/A49G/D86N/K132N/R276W; P2T/A49G/K132N; P2T/A49G/K132N/P168S/S233K/I267V/R276W; P2T/A49G/K132N/G227D/P252C/R276W; P2T/A49G/K132N/G227D/R276W; P2T/A49G/K132N/S233K/I267V/R276W; P2T/A49G/K132N/S233K/R276W; P2T/A49G/K132N/I267V/R276W; P2T/A49G/K132N/R276W; PT2/A49G/K152E; P2T/A49G/K152E/P168S/S233V/I267V/R276W; P2T/A49G/K152E/I267V/R276W; P2T/A49G/K152E/R276W; P2T/A49G/P168S/R206S/I267V/R276W; P2T/A49G/P168S/S233K/R276W; P2T/A49G/P168S/R276W; P2T/A49G/R206S/S233K/I267V/R276W; P2T/A49G/R206S; S233V/R276W P2T/A49G/R206S/R276W; P2T/A49G/G227D/P252C/G264D/R276W; P2T/A49G/G227D/P252C/R276W; P2T/A49G/G227D/I267V/R276W; P2T/A49G/G227D/R276W; P2T/A49G/S233K/R276W; P2T/A49G/S233K/I267V/R276W; P2T/A49G/S233V/A246L/R276W/N302S; P2T/A49G/S233V/A246L/N302S; P2T/A49G/S233V/I267V/R276W; P2T/A49G/S233V/R276W; P2T/A49G/P252C/R276W; P2T/A49G/S261N; P2T/A49G/S261N/R276W; P2T/A49G/I267V/R276W; P2T/A49G/R276W; P2T/A46G/R276W/N302S; P2T/A49G/R276W/V318C; P2T/A49G/N302S; P2T/A49G/V319C; P2T/K132A; P2T/K132A/R276W; P2T/K132N; P2T/K132N/R276W; P2T/K132N/K152E; P2T/K132N/K152E/R276W; P2T/G157R; P2T/G157R/R276W; P2T/P168S; P2T/P168S/R276W; P2T/R206S; P2T/R206S/R276W; P2T/A246L; P2T/A246L/R276W; P2T/A266C; P2T/R276W; P2T/R276W/V318C; P2T/V318C; S3H/R33L/A56E; S3H/R33L/A56E/R276W; S3H/R33L/T114S; S3H/R33L/T114S/R276W; S3H/T114S/N302S; S3H/T114S/R276W/N302S; S3H/R276W; D11K/K155Y/R206S; D11K/K155Y/R206S/R276W; D11K/V255I/R276M; D11K/R276W; D23E/K68R; R33L/A56E; R33L/A56E/R276W; R33L/R276W; K36Q/R276W; E46K/D47N; A49G/K132A; A49G/K132A/K152E; A49G/K132A/K152E/R276W; A49G/K132A/R206S; A49G/K132A/R276W; A49G/K132A/R206S/R276W; A49G/K132N/K152E/R276W; A49G/K132N/K152E/R276W/N302S; A49G/K132N/K152E/N302S; A49G/K132N/R206S/S233V/W276M/N302S; A49G/K132N/R206S/S233V/R276M/N302S; A49G/K152E; A49G/K152E/R276W; A49G/K152E; D11K/V255I/W276M; A49G/R276W; K52R/R276W; A56E/T114S; A56E/T114S/R276W; T114S/R276W; K132N/R276W; K132N/K155R/R276W/V283H; K132N/K155R/V283H; K155R/R206S; K155R/R206S/R276W; P168S/R276W; G227D/R276W; P252C/R276W; K270R/N272P/R276F; N272P/R276F; and/or R276W/V318C, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:2.

### Claim 4 (depends on 1)

The isolated xylose reductase variant of claim 1, wherein, said variant comprises the polypeptide sequence set forth in SEQ ID NOS:41, 43, 45, 47, 51, 55, 57, and/or 59.

### Claim 5 (depends on 4)

An isolated nucleic acid sequence encoding the isolated xylose reductase variant of claim 4, and/or an isolated nucleic acid sequence comprising SEQ ID NO:3, 4, 40, 42, 44, 46, 50, 54, 56, and/or 60.

### Claim 6

A recombinant nucleic acid construct comprising at least one polynucleotide sequence that encodes at least one xylose reductase, wherein the polynucleotide is selected from: (a) a polynucleotide that encodes a polypeptide comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% identity to SEQ ID NO:2, wherein the amino acid sequence comprises at least one substitution set forth herein; (b) a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a polynucleotide that encodes a polypeptide having the amino acid sequence of SEQ ID NO:2, and wherein said amino acid sequence comprises at least one substitution set forth herein; and (c) a nucleic acid construct comprising SEQ ID NO:3 and/or SEQ ID NO:4 and/or at least a portion of SEQ ID NO:3 and/or SEQ ID NO:4.

### Claim 7 (depends on 6)

The recombinant nucleic acid construct of claim 6, wherein said polynucleotide sequence encodes a polypeptide having an amino acid sequence that comprises at least one substitution at position 2, 3, 7, 11, 14, 17, 19, 20, 23, 24, 33, 36, 46, 47, 49, 56, 62, 63, 68, 86, 89, 97, 102, 107, 108, 114, 116, 123, 132, 134, 143, 152, 155, 157, 162, 168, 184, 206, 219, 224, 225, 226, 227, 228, 246, 231, 232, 233, 236, 240, 242, 245, 246, 249, 252, 255, 261, 264, 266, 267, 270, 271, 272, 275, 276, 279, 281, 282, 283, 285, 297, 299, 301, 302, 303, and/or 318, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:2.

### Claim 8 (depends on 7)

The recombinant nucleic acid construct of claim 7, wherein said polynucleotide sequence encodes a polypeptide having an amino acid sequence that comprises at least one substitution selected from P2T, S3H, S3R, S3W, S3X, N7L, D11K, A14V, F17W, C19L, W20X, D23E, V24G, R33L, R33V, K36Q, E46C, E46K, D47G, D47N, A49G, K52R, A56E, A56Y, I62V, D63X, K68G, K68M, K68R, D86N, E89N, E89V, S97R, S97T, D102T, F107Y, L108Y, T114S, K116Q, K123C, K132A, K132N, D134E, D134H, D134V, I143L, K152A, K152E, K152H, K152Q, K155A, K155D, K155I, K155R, K155Y, G157R, I162L, P168S, S184A, R206S, R206V, Q219H, Q219L, Q219T, L224A, L224S, L224V, N225D, N225E, N225K, N225S, N225Y, Q226D, Q226E, Q226S, Q226V, G227D, R228T, N231G, N231H, N231L, N231S, T232A, T232C, T232S, T232V, S233C, S233F, S233G, S233I, S233K, S233V, S233X, F236L, T240V, K242L, A245S, A246L, A246S, G249D, P252C, V255I, S261A, S261C, S261N, S261T, G264D; A266V, A266C, I267V, I267X, K270R, S271G, N272P, P275A, R276M, R276F, R276W, W276M, E279Q, K281L, K281V, D282C, D282G, D282R, V283H, S285E, S285T, A297H, A297S, L299X, I301C, I301Y, N302D, N302G, N302S, L303I, L303V, and/or V318C, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:2.

### Claim 9 (depends on 6)

The recombinant nucleic acid construct of claim 6, wherein said polynucleotide sequence encodes a polypeptide having an amino acid sequence that comprises at least one substitution set selected from P2T/S3H/A49G/P168S/S233K/R276W; P2T/S3X/A49G/S233X/I267X/R276W/L299X; P2T/C19L/E46C/A49G/F107Y/K132N/S233K/I267V/R276W; P2T/C19L/E46C/A49G/K132N/S233K/I267V/R276W; P2T/W20X/A49G/D63X/R276W; P2T/V24G/A49G; P2T/V24G/A49G/R276W; P2T/V24G/R276W/V318C; P2T/V24G/V318C; P2T/K36Q/A49G/G227D/R276W; P2T/E46C/A49G/F107Y/K132N/S233K/I267V/R276W; P2T/E46C/A49G/K132N/V164I/S233K/I267V/R276W; P2T/A49G; P2T/A49G/K52R/K152E/S233K/I267V/R276W; P2T/A49G/K52R/R206S/I267V/R276W; P2T/A49G/K52R/R276W; P2T/A49G/K68G/S261N/R276W/V318C; P2T/A49G/K68G/S261N/V318C; P2T/A49G/D86N/K132N/R276W; P2T/A49G/K132N; P2T/A49G/K132N/P168S/S233K/I267V/R276W; P2T/A49G/K132N/G227D/P252C/R276W; P2T/A49G/K132N/G227D/R276W; P2T/A49G/K132N/S233K/I267V/R276W; P2T/A49G/K132N/S233K/R276W; P2T/A49G/K132N/I267V/R276W; P2T/A49G/K132N/R276W; PT2/A49G/K152E; P2T/A49G/K152E/P168S/S233V/I267V/R276W; P2T/A49G/K152E/I267V/R276W; P2T/A49G/K152E/R276W; P2T/A49G/P168S/R206S/I267V/R276W; P2T/A49G/P168S/S233K/R276W; P2T/A49G/P168S/R276W; P2T/A49G/R206S/S233K/I267V/R276W; P2T/A49G/R206S; S233V/R276W P2T/A49G/R206S/R276W; P2T/A49G/G227D/P252C/G264D/R276W; P2T/A49G/G227D/P252C/R276W; P2T/A49G/G227D/I267V/R276W; P2T/A49G/G227D/R276W; P2T/A49G/S233K/R276W; P2T/A49G/S233K/I267V/R276W; P2T/A49G/S233V/A246L/R276W/N302S; P2T/A49G/S233V/A246L/N302S; P2T/A49G/S233V/I267V/R276W; P2T/A49G/S233V/R276W; P2T/A49G/P252C/R276W; P2T/A49G/S261N; P2T/A49G/S261N/R276W; P2T/A49G/I267V/R276W; P2T/A49G/R276W; P2T/A46G/R276W/N302S; P2T/A49G/R276W/V318C; P2T/A49G/N302S; P2T/A49G/V319C; P2T/K132A; P2T/K132A/R276W; P2T/K132N; P2T/K132N/R276W; P2T/K132N/K152E; P2T/K132N/K152E/R276W; P2T/G157R; P2T/G157R/R276W; P2T/P168S; P2T/P168S/R276W; P2T/R206S; P2T/R206S/R276W; P2T/A246L; P2T/A246L/R276W; P2T/A266C; P2T/R276W; P2T/R276W/V318C; P2T/V318C; S3H/R33L/A56E; S3H/R33L/A56E/R276W; S3H/R33L/T114S; S3H/R33L/T114S/R276W; S3H/T114S/N302S; S3H/T114S/R276W/N302S; S3H/R276W; D11K/K155Y/R206S; D11K/K155Y/R206S/R276W; D11K/V255I/R276M; D11K/R276W; D23E/K68R; R33L/A56E; R33L/A56E/R276W; R33L/R276W; K36Q/R276W; E46K/D47N; A49G/K132A; A49G/K132A/K152E; A49G/K132A/K152E/R276W; A49G/K132A/R206S; A49G/K132A/R276W; A49G/K132A/R206S/R276W; A49G/K132N/K152E/R276W; A49G/K132N/K152E/R276W/N302S; A49G/K132N/K152E/N302S; A49G/K132N/R206S/S233V/W276M/N302S; A49G/K132N/R206S/S233V/R276M/N302S; A49G/K152E; A49G/K152E/R276W; A49G/K152E; D11K/V255I/W276M; A49G/R276W; K52R/R276W; A56E/T114S; A56E/T114S/R276W; T114S/R276W; K132N/R276W; K132N/K155R/R276W/V283H; K132N/K155R/V283H; K155R/R206S; K155R/R206S/R276W; P168S/R276W; G227D/R276W; P252C/R276W; K270R/N272P/R276F; N272P/R276F; and/or R276W/V318C, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:2.

### Claim 10 (depends on 6)

The recombinant nucleic acid construct of claim 6, wherein the polynucleotide sequence is at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% identical to SEQ ID NO:1, and wherein said polynucleotide sequence comprises at least one mutation selected from t6g, t7a, c8g, t9c, c21t, c54t, t82a, c83g, t84a, t84w, t99a, t99g, g108a, c111n, g156a, c168a, c201t, g204a, g231a, a280c, t289a, c290g, t291c, c306t, t322c, g324a, t354g, t358c, a378t, g513t, c360g, a378t, c402t, c408t, a426t, c438t, g456a, g465a, a478c, a478g, g480t, a504g, t511c, g513a, g513t, t552c, t552g, a585g, t618c, t670c, g672t, t688c, t697a, c698g, t699c, t703c, t747c, t751a, c752g, t753c, t753g, a756c, a756t, t766c, t781a, c782g, c801t, t811a, c812g, c816t, c822t, a825c, a826c, g834a; c849g, a853t, g854c, c855g, c855t, t895c, c906t, t907c, and/or c954g, wherein the nucleotide position is determined by alignment with SEQ ID NO:1.

### Claim 11 (depends on 10)

The nucleic acid construct of claim 10, wherein the polynucleotide sequence comprises at least one mutation and/or mutation set selected from t6g/t781a/c782g/a853t/g854c; t6g/t781a/a853t; t7a/c8g; t7a/c8g/g456a; t7a/g456a; t9c/t84a/g231a/t697a/c698g/t895c; t9c/t618c; t9c/t895c; t82a/c83g; t82a/c83g/c201t; t82a/c83g/c201t/t358c/a378t/t511c; t84a; t84w; t99a; t99a/g108a/g156a/t322c/t747c/t751a/c752g/t753c; t99a/g108a/g156a/t322c/g513a/t747c/t751a/c752g/t753c/c816t; t99a/g108a/g156a/t747c/t751a/c752g/t753c/c801t; t99a1g156a; t99a/g156a/g204a; t99a/g156a/t322c/t747c/t751a/c752g/t753c; t99a/g156a/t552g/t747c/t751a/c752g/t753c; t99a/g156a/t747c/t751a/c752g/t753c; t99a/g204a; t99a/g204a/t618c/t697a/c698g/t699c/t747c/t751a/c752g/t753c; t99a/g513a/t747c/t751a/c752g/t753c; t99a/t618c/t747c/t751a/c752g/t753c; t99a/t697a/c698g/t699c/t747c/t751a/c752g/t753c; t99a/t747c/t751a/c752g/t753c; t99g/g108a/a853t/g854c/c855g; t99g/c168a; t99g/t753g/a756t/a853t/g854c/c855g; g108a1t289a; g108a/t289a/c290g/t291c; g108a/g465a; g108a/t907c; c111n/c822t/a825c/a853t/g854c/c855g; g156a; g156a/g204a/c801t; g156a/g231a/t322c/g456a/t895c; g156a/t747c/t751a/c752g/t753c; c201t/a3c; g204a; g204a/a478c/g480t/t753g/a756t/a853t/g854c/c855g; g204a/t697a/c698g/t699c/t747c/t751a/c752g/t753c; g204a/t753g/a756t/a853t/g854c/c855g; g204a/c801t; g231a/t322c; g231a/t322c/t895c; g231a/c801t; a280c/a282t; t289a1c290g/t291c; t322c/t895c; g324a/c402t/a853t/g854c/c954g; g324a/c402t/a853t/c954g; t358c/a360g; g456a/c801t/t895c; g456a/t895c; g465a/t618c/t907c; a478c/g480t; a478c/g480t/t753g/a756t/a853t/g854c/c855g; a504g; a504g/c816t/t895c; a504g/t895c; t511c/g513t; t552g/c801t/t895c; t618c/t697a/c698g/c801t/t895c; t618c/t895c; t618c/c747c/t751a/c752g/t753c; g670c/g672; t697a/c698g/t699c; t697a/c698g/c801t/t895c; t699c/a756c; t747c/t751a/c752g/t753c; t753g; t753g/a756t/a853t/g854c/c855g; t753g/a853t/g854c/c855g; a756t/c816t; t781a/c782g/c954g; t781a/c954g; c801t; c801t/t895c; t811a/c812g; t811a/c812g/c816t; 811a/c812g/c816t/a826c/a828t; c816t/a826c/a828t; t829a/c83g; g834a/t895c; a853t/g854c; a853t/g854c/c855g; a853t/g854c/c954g; and/or a853t/c954g; t895c; wherein the nucleotide position is determined by alignment with SEQ ID NO:1.

### Claim 12

A recombinant nucleic acid construct comprising at least one polynucleotide sequence encoding a xylitol dehydrogenase, wherein said polynucleotide is selected from: (a) a polynucleotide that encodes a polypeptide comprising an amino acid sequence having at least about 70%, at least 80%, at least 85%, at least 90%, or at least 95% identity to SEQ ID NO:6, wherein said amino acid sequence comprises at least one substitution set forth herein; and (b) a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a polynucleotide that encodes a polypeptide having the amino acid sequence of SEQ ID NO:6, wherein said amino acid sequence comprises at least one substitution set forth herein.

### Claim 13 (depends on 12)

The nucleic acid construct of claim 12, wherein said polynucleotide sequence encodes a polypeptide comprising at least a portion of the amino acid sequence set forth in SEQ ID NO:6, wherein said amino acid sequence comprises at least one substitution at position 5, 13, 19, 26, 49, 81, 112, 149, 187, 189, 202, 205, 206, 208, 209, 210, 211, 214, 215, 218, 225, 226, 227, 228, 229, 230, 231, 232, 235, 238, 239, 241, 251, 252, 256, 259, 260, 286, 287, 296, 307, 327, 337, 350, and/or 352, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:6.

### Claim 14 (depends on 13)

The nucleic acid construct of claim 13, wherein said polynucleotide sequence encodes a polypeptide having an amino acid sequence that comprises at least one substitution selected from P5E, P5R, D13G, T19L, T19Q, S26A, A49Q, S81G, H112A, H112Q, H149R, V187M, L189C, G202D, V205C, V205H, V206A, I208R, F209S, D210A, D210W, N211K, N211R, N211S, K214A; M215A, M215C, D218R, T225X, F226V, N227T, S228P, K229M, K229R, K229V, T230V, G231A, G231H, G232R, E235K, E235Q, K238G, K337R, A239C, G241E, G241W, C251A, C251G, C251T, T252S, P256A, P256Q, K259S, L260Q, T286V, V287L, F296R, K307R, D327A, D327X, A350D, K352E, K352G, and/or K352Q, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:6.

### Claim 15 (depends on 12)

The nucleic acid construct of claim 12, wherein said polynucleotide sequence encodes a polypeptide having an amino acid sequence that comprises at least one substitution set selected from A49Q/E235K; I208R/N211K; F209S/N211K; and G241W/K307R, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:6.

### Claim 16 (depends on 12)

The nucleic acid construct of claim 12, wherein the polynucleotide sequence is at least about 80%, at least about 85%, at least about 90%, or at least about 95% identical to SEQ ID NO:5, and wherein said polynucleotide sequence comprises at least one mutation set forth herein.

### Claim 17 (depends on 12)

The nucleic acid construct of claim 12, wherein the polynucleotide sequence comprises a mutation in at least one position selected from t24g, c336t, c630t, a693w, a732g, a768t, and/or a780g, wherein nucleotide position is determined by alignment with SEQ ID NO:5.

### Claim 18 (depends on 12)

The nucleic acid construct of claim 12, wherein said construct comprises at least one isolated nucleic acid sequence selected from SEQ ID NOS:7, 8, 48, and/or 52.

### Claim 19

An isolated xylitol dehydrogenase variant, wherein said variant has xylitol dehydrogenase activity and comprising a substitution at one or more positions selected from 5, 13, 19, 26, 49, 81, 112, 149, 187, 189, 202, 205, 206, 208, 209, 210, 211, 214, 215, 218, 225, 226, 227, 228, 229, 230, 231, 232, 235, 238, 239, 241, 251, 252, 256, 259, 260, 286, 287, 296, 307, 327, 337, 350, and/or 352, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:6.

### Claim 20 (depends on 19)

The isolated xylitol dehydrogenase variant of claim 19, wherein said variant has xylitol dehydrogenase activity and comprising a substitution at one or more positions selected from P5E, P5R, D13G, T19L, T19Q, S26A, A49Q, S81G, H112A, H112Q, H149R, V187M, L189C, G202D, V205C, V205H, V206A, I208R, F209S, D210A, D210W, N211K, N211R, N211S, K214A; M215A, M215C, D218R, T225X, F226V, N227T, S228P, K229M, K229R, K229V, T230V, G231A, G231H, G232R, E235K, E235Q, K238G, K337R, A239C, G241E, G241W, C251A, C251G, C251T, T252S, P256A, P256Q, K259S, L260Q, T286V, V287L, F296R, K307R, D327A, D327X, A350D, K352E, K352G, and/or K352Q, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:6.

### Claim 21 (depends on 20)

The isolated xylitol dehydrogenase variant of claim 20, wherein said variant has xylitol dehydrogenase activity, comprising at least one of the following substitution sets A49Q/E235K; I208R/N211K; F209S/N211K; G241W/K307R, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:6.

### Claim 22 (depends on 19)

The isolated xylitol dehydrogenase variant of claim 19, wherein said variant comprises the sequence set forth in SEQ ID NO:49 and/or SEQ ID NO:53.

### Claim 23

A recombinant nucleic acid construct comprising polynucleotide sequences encoding at least one variant xylose reductase and at least one variant xylitol dehydrogenase.

### Claim 24 (depends on 23)

The recombinant nucleic acid construct of claim 23, wherein said polynucleotide sequences encode at least one xylose reductase and at least one xylitol dehydrogenase, wherein said polynucleotide sequences are selected from SEQ ID NOS:1, 3, 4, 40, 42, 44, 46, 50, 54, 56, and/or 58; and SEQ ID NOS:5, 7, 8, 48, and/or 52.

### Claim 25 (depends on 24)

The recombinant nucleic acid construct of claim 24, wherein said polynucleotide sequence encoding at least one xylose reductase comprises at least one mutation or mutation set selected from t9c/t618c; t9c/t895c; t9c/t84a/g232a/t697a; c698g/t895c; t9c/t84a/g231a/t697a/t895c; t84a; t84w; t99a; t99a/g156a; t99a/g156a/t747c/t751a; t99a/g156a/g204a; t99a/g156a/t747c/t751a/c752g/t753c; t99a/g204a/t618c/t697a/t747c/t751a; t99a/g204a/t618c/t697a/c698g/t699c/t747c/t751a/c752g/t753c; t99a/g204a; t99a/g513a/t747c/t751a; t99a/g513a/t747c/t751a/c752g/t753c; t99a/t618c/t747c/t751a; t99a/t618c/t747c/t751a/c752g/t753c; t99a/t697a/c698g/t696c/t747c/t751a/c752g/t753c; t99a/t697a/t747c/t751a; t99a/t747c/t751a; t99a/t747c/t751a/c752g/t753c; t99g/g108a/a853t; t99g/t753g/a756t/a853t; c111n/c822t/a825c/a853t; c111n/c822t/a825c/a853t/g854c/c855g; g156a; g156a/g204a/c801t; g156a/g204a/c801t/t753g/a756t/a853t; g156a/g231a/t322c/g456a/t895c; g156a/a478c; g156a/t747c/t751a; g156a/t747c/t751a/c752g/753c; g204a/a478c/t753/a756t/a853t; g204a/t697a/t747c/t751a; g204a/t697a/c698g/t699c/t747c/t751a/c752g/t753c; g204a/t753g/a756t/a853t; g204a/c801t; g231a/t322c; g231a/t322c/t895c; a280c/a282t; t322c/t618c/t895c; t322c/t895c; t358c/a360g; g456a/c801c/t747c/t751a; a478c/t753g/a756t/a853t; a478c/g480t/t753g/a756t/a853t/g854c/c855g; g456a/c801t/t895c; g456a/t895c; a504g; a504g/c816t; a504g/c816t/t895c; a504g/t895c; t511c/g513t; t552g/c801t/t895c; t618c/t697a/c698g/c801t/t895c; t618/t747c/t751a; t618c/t747c/t751a/c752g/t753c; t618c/t895c; t697a; t697a/c698g/c801t/t895c; t697a/c801t/t895c; t747c/t751a; t753g; t753g/a853t/g854c/c855g; t753g/a756t; t753g/a756t/a853t/g854c/c855g; t753g/a853t; c801t; c801t/t895c; t811a/c812g; t811a/c812g/c816t; t811a/c812g/c816t/a826c/a828t; t811a/c816t; c816t/a826c/a828t; g834a/t895c; a853t; a853t/a854c/c855g; and/or t895c, wherein the nucleotide position is determined by alignment with SEQ ID NO:1; and wherein said polynucleotide sequence encoding said at least one xylitol dehydrogenase comprises at least one mutation selected from t24g, c336t, a630t, a693w, c693w, a768t, a732g, a780g, a780t, wherein the nucleotide position is determined by alignment with SEQ ID NO:6.

### Claim 26 (depends on 25)

The recombinant nucleic acid construct of claim 25, further comprising at least one polynucleotide sequence encoding at least one xylulokinase, wherein said polynucleotide sequence comprises SEQ ID NO:11 and/or SEQ ID NO:12.

### Claim 27

A recombinant nucleic acid construct comprising at least one sequence selected from SEQ ID NOS:1, 3, 4, 5, 7, 8, 11, 12, 40, 42, 44, 46, 48, 50, 52, 54, 55, 56, and/or 58.

### Claim 28

An isolated combinatorial variant, wherein said variant has xylose reductase and xylitol dehydrogenase activities, wherein said xylose reductase comprises at least one substitution at one or more positions selected from 2, 3, 7, 11, 14, 17, 19, 20, 23, 24, 33, 36, 46, 47, 49, 56, 62, 63, 68, 86, 89, 97, 102, 107, 108, 114, 116, 123, 132, 134, 143, 152, 155, 157, 162, 168, 184, 206, 219, 224, 225, 226, 227, 228, 246, 231, 232, 233, 236, 240, 242, 245, 246, 249, 252, 255, 261, 264, 266, 267, 270, 271, 272, 275, 276, 279, 281, 282, 283, 285, 297, 299, 301, 302, 303, and/or 318, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:2; and, wherein said xylitol dehydrogenase comprises at least one substitution at one or more positions selected from 5, 13, 19, 26, 49, 81, 112, 149, 187, 189, 202, 205, 206, 208, 209, 210, 211, 214, 215, 218, 225, 226, 227, 228, 229, 230, 231, 232, 235, 238, 239, 241, 251, 252, 256, 259, 260, 286, 287, 296, 307, 327, 337, 350, and/or 352, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:6.

### Claim 29 (depends on 28)

The isolated combinatorial variant of claim 28, wherein said at least one xylose reductase comprises at least one substitution and/or substitution set selected from P2T/S3H/A49G/P168S/S233K/R276W; P2T/S3X/A49G/S233X/I267X/R276W/L299X; P2T/K132N/K152E/R276W; P2T/W20X/A49G/D63X/R276W; P2T/A49G/K52R/K152E/S233K/I267V/R276W; P2T/A49G/K52R/R206S/I267V/R276W; P2T/A49G/K52R/R276W; P2T/A49G/K132N/G227D/P252C/R276W; P2T/A49G/K132N/G227D/R276W; P2T/A49G/K132N/S233K/I267V/R276W; P2T/A49G/K132N/I267V/R276W; P2T/A49G/K132N/R276W; P2T/A49G/K152E/P168S/S233V/I267V/R276W; P2T/A49G/P168S/R206S/I267V/R276W; P2T/A49G/P168S/S233K/R276W; P2T/A49G/P168S/R276W; P2T/A49G/R206S/S233K/R276W; P2T/A49G/R206S/S233K/I267V/R276W; P2T/A49G/R206S/R276W; P2T/A49G/G227D/P252C/G264D/R276W; P2T/A49G/G227D/P252C/R276W; P2T/A49G/G227D/I267V/R276W; P2T/A49G/G227D/R276W; P2T/A49G/S233K/R276W; P2T/A49G/S233K/I267V/R276W; P2T/A49G/S233V/R276W; P2T/A49G/S233V/I267V/R276W; P2T/A49G/P252C/R276W; P2T/A49G/I267V/R276W; P2T/A49G/C276W; P2T/A49G/R276W; P2T/K132N/K152E/R276W; P2T/R206S/R276W; S3H/P168S/S233K; S3X/S233X/I267X/L299X; W20X/D63X; K36Q/G227D; K52R/R206S/I267V; K52R/K152E/S233K/I267V; D86N/K132N; K132N/I267V; K132N/G227D; K132N/233K/I267V; K132N/G227D/P252C; K152E/P168S/S233V/I267V; K152E/I267V; P168S/S233K; P168S/R206S/I267V; R206S/S233V; R206S/S233X/I267V; R206S/S233K/I267V; G227D/I267V; G227D/P252C; G227D/P252C/G264D; S233K/I267V; S233V/I267V; K52R; K132N; P168S; R206S; G227D; S233K; S233V; P252C; 1267V; K270R; S271G; N272P; and/or R276F, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:2; and wherein said at least one xylitol dehydrogenase comprises at least one substitution and/or substitution set selected from S26A; A49Q; A49Q/E235K; H112A; H112Q; V206A; I208R/F209S/N211S; I208R/N211K; I208R/N211R; I208R/N211S; F209S; F209S/N211K; D210A; N211K; N211R; N211S; K214A; T225X; K229M; K229V; G232L; G232R; E235K; K337R; K238G; G241E; C251A; K259S; V287L; D327X; K352E; K352G; and/or K352Q, wherein the positions are numbered by correspondence with the amino acid sequence set forth in SEQ ID NO:6.

### Claim 30

A nucleic acid construct comprising at least one polynucleotide encoding at least one xylose reductase and/or xylitol dehydrogenase variant as provided in Table 4-1, 4-2, 4-3, 4-4, and/or 4-5.

### Claim 31 (depends on 30)

The xylose reductase variant and/or xylitol dehydrogenase variant encoded by the polynucleotide of claim 30.

### Claim 32

A nucleic acid construct comprising at least on polynucleotide encoding at least one xylose reductase and xylitol dehydrogenase combinatorial variant as provided in Table 4-6 and/or Table 4-1.

### Claim 33 (depends on 32)

The xylose reductase and xylitol dehydrogenase combinatorial variant encoded by the xylose reductase and xylitol dehydrogenase combinatorial variant of claim 32.

### Claim 34 (depends on 32)

A recombinant fungal host cell comprising at least one polynucleotide sequence encoding at least one xylose reductase and/or xylitol dehydrogenase variant, as provided in claim 32.

### Claim 35

A recombinant fungal host cell comprising at least one polynucleotide sequence encoding at least one xylose reductase, wherein said polynucleotide sequence comprises SEQ ID NOS:1, 3, 4, 40, 42, 44, and/or 46; and at least one polynucleotide encoding at least one xylitol dehydrogenase, wherein said polynucleotide sequence comprises SEQ ID NOS:5, 7, 8, and/or 48.

### Claim 36 (depends on 35)

The recombinant fungal host cell of claim 35, further comprising at least one polynucleotide encoding at least one xylulokinase, wherein said polynucleotide comprises SEQ ID NO:11 and/or 12.

### Claim 37 (depends on 34)

A process for producing a fermentation product, comprising:
(a) providing the recombinant fungal host cell of claim 34;
(b) providing a fermentation medium comprising; and
(c) contacting said fermentation medium with said recombinant fungal host cell under conditions suitable for generating said fermentation product.

### Claim 38 (depends on 38)

The process of claim 38, further comprising (d) recovering said fermentation product.
